Prilenia Therapeutics
Developing New Treatments for Neurodegenerative Diseases
StartupPrilenia Therapeutics is a Yakum-based startup in the Health Tech & Life Sciences sector, established in 2018. Developing New Treatments for Neurodegenerative Diseases. The company has raised a total of $144.5M across 4 funding rounds, currently at the B stage. Key investors include SV Health Investors, Talisman Capital Partners, Sectoral Asset Management, among 9 total investors. The company has 51-200 employees. Core technologies: Biologicals.
With $144.5M in total funding, Prilenia Therapeutics is a B-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageB
- ProductClinical Trial
- ModelB2B
- Employees51-200
- HQYakum
- Last Round$11M
- SV Health Investors
- Talisman Capital Partners
- Sectoral Asset Management
9 investors total
11 articles covered by sources including huntingtonsdiseasenews.com,
www.businesswire.com,
alsnewstoday.com,
www.newswise.com,
www.finsmes.com.
What does Prilenia Therapeutics do?
Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The initial focus of the company has been on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). Prilenia's lead compound is pridopidine (45 mg twice daily), a first-in-class, oral, highly selective and potent investigational S1R agonist that is in pre-registration for HD and Phase 3-stage development for ALS. Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD. Prilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund.
How much funding has Prilenia Therapeutics raised?
Prilenia Therapeutics has raised $144.5M in total funding across 4 rounds. The company is currently at the B stage. Key investors include SV Health Investors, Talisman Capital Partners, Sectoral Asset Management.
What sector is Prilenia Therapeutics in?
Prilenia Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.
Where is Prilenia Therapeutics located?
Prilenia Therapeutics is based in Yakum, Israel. The company also has offices abroad.